Read
Sponsored Links
Insmed's lung infection drug succeeds in late-stage trial
July 1 |
July 1 (Reuters) - Insmed Inc said a late-stage trial of its experimental lung infection drug showed the therapy was as effective as another approved treatment.
The drug, Arikace, was being tested as a treatment for a bacterial infection in cystic fibrosis patients. The trial met its main goal of showing Arikace was not inferior to Tovi, Novartis's drug for the same infection.
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
Nighty wrote:
Yay!!!
Follow Reuters